Actively Recruiting
Phase 3 Randomized Trial of Reltodecacog Alfa Compared to Usual Care in Patients on FXa DOACs Undergoing Urgent Surgery or High-Bleed Risk Procedures
Led by VarmX B.V. · Updated on 2026-10-14
800
Participants Needed
77
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating reltodecacog alfa VMX-C001 to see if it can help control blood clotting in patients who take FXa Direct Oral Anticoagulants DOACs and need urgent surgery or other invasive procedures that carry a high risk of bleeding. This study compares a fixed dose of reltodecacog alfa to the usual pharmacological care given during such procedures. The main question is whether bleeding stops effectively during the procedure as judged by experts unaware of the treatment given. Participants will receive either a fixed dose of reltodecacog alfa before their procedure or the usual treatment used at the study site for patients on FXa DOACs. Both groups will undergo their required surgery or invasive procedure with or without planned heparin administration. The treatment is given prior to the procedure, and participants are monitored throughout their hospital stay. During the study, participants will have regular clinical assessments and laboratory tests while hospitalized after the procedure. They will return to the clinic approximately 28 days later for follow-up checks and tests. Researchers will measure the effect of the interventions on haemostasis, bleeding severity, blood loss, and anticoagulation levels using specific laboratory tests. The total participation duration extends from pre-procedure through follow-up about one month later.
CONDITIONS
Brief Title
Phase 3 Trial of Reltodecacog Alfa (VMX-C001) vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin.
Research Team
H
Head of Clinical Operations
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here